Tag: apixaban
-
DOAC Outcomes in NVAF Linked to Echocardiographic Hemodynamics
Overview: DOACs, NVAF, and the role of cardiac hemodynamics Non-valvular atrial fibrillation (NVAF) requires careful stroke prevention, with direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran replacing warfarin in many patients. While DOACs have demonstrated non-inferiority to warfarin in large trials, real-world data reveal nuances in bleeding and stroke risk that may hinge…
-
Echocardiographic Hemodynamics Reveal DOAC-Specific Bleeding and Stroke Differences in Non-Valvular Afib
Background: DOACs, NVAF, and the bleeding-stroke balance Atrial fibrillation (AF) and atrial flutter (AFL) elevate stroke risk, driving the widespread use of oral anticoagulants. Direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, and edoxaban—offer non-inferiority to warfarin with distinct bleeding profiles. In real-world practice, apixaban often shows the lowest overall bleeding, particularly GI bleeding, while rivaroxaban and…